Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Lung Cancer

  Free Subscription


Articles published in JAMA Oncol

Retrieve available abstracts of 63 articles:
HTML format



Single Articles


    June 2020
  1. KAS B, Talbot H, Ferrara R, Richard C, et al
    Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Jun 11. pii: 2766806. doi: 10.1001/jamaoncol.2020.1634.
    PubMed     Abstract available


  2. LE PECHOUX C, Levy A
    Radiosurgery in Patients With Small Cell Lung Cancer With Brain Metastases: A Call for Prospective Evidence.
    JAMA Oncol. 2020 Jun 4. pii: 2766562. doi: 10.1001/jamaoncol.2020.1245.
    PubMed    


  3. RUSTHOVEN CG, Yamamoto M, Bernhardt D, Smith DE, et al
    Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study.
    JAMA Oncol. 2020 Jun 4. pii: 2766565. doi: 10.1001/jamaoncol.2020.1271.
    PubMed     Abstract available


  4. BERCHUCK JE, Meyer CS, Zhang N, Berchuck CM, et al
    Association of Mental Health Treatment With Outcomes for US Veterans Diagnosed With Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Jun 4. pii: 2766567. doi: 10.1001/jamaoncol.2020.1466.
    PubMed     Abstract available


    May 2020
  5. MIYAMOTO S, Azuma K, Ishii H, Bessho A, et al
    Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
    JAMA Oncol. 2020 May 14:e201250. doi: 10.1001/jamaoncol.2020.1250.
    PubMed     Abstract available


  6. LIU Y, Colditz GA, Kozower BD, James A, et al
    Association of Medicaid Expansion Under the Patient Protection and Affordable Care Act With Non-Small Cell Lung Cancer Survival.
    JAMA Oncol. 2020 May 14. pii: 2765753. doi: 10.1001/jamaoncol.2020.1040.
    PubMed    


    April 2020
  7. SANCHEZ A, Furberg H
    Obesity Paradox in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy.
    JAMA Oncol. 2020 Apr 23. pii: 2764900. doi: 10.1001/jamaoncol.2020.0634.
    PubMed    


  8. KICHENADASSE G, Hopkins AM, Sorich MJ
    Obesity Paradox in Patients With Non-Small Cell Lung Cancer Treated With Immunotherapy-Reply.
    JAMA Oncol. 2020 Apr 23. pii: 2764902. doi: 10.1001/jamaoncol.2020.0643.
    PubMed    


  9. RIZVI NA, Cho BC, Reinmuth N, Lee KH, et al
    Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2020 Apr 9. pii: 2763864. doi: 10.1001/jamaoncol.2020.0237.
    PubMed     Abstract available


  10. WAQAR SN, Govindan R
    The Mystic Role of Tumor Mutational Burden in Selecting Patients With Lung Cancer for First-Line Immunotherapy.
    JAMA Oncol. 2020 Apr 9. pii: 2763860. doi: 10.1001/jamaoncol.2020.0264.
    PubMed    


  11. ARRIETA O, Barron F, Ramirez-Tirado LA, Zatarain-Barron ZL, et al
    Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2020 Apr 9. pii: 2763865. doi: 10.1001/jamaoncol.2020.0409.
    PubMed     Abstract available


    March 2020
  12. YANG JJ, Yu D, Shu XO
    Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk-Reply.
    JAMA Oncol. 2020 Mar 19. pii: 2762588. doi: 10.1001/jamaoncol.2020.0270.
    PubMed    


  13. WU Q, Leung EL
    Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk.
    JAMA Oncol. 2020 Mar 19. pii: 2762586. doi: 10.1001/jamaoncol.2020.0261.
    PubMed    


  14. ARRIETA O, Ramirez-Tirado LA, Zatarain-Barron ZL
    Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2020 Mar 12. pii: 2762582. doi: 10.1001/jamaoncol.2020.0062.
    PubMed    


  15. GAO C, Cai S, He Y
    Metformin Plus Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer.
    JAMA Oncol. 2020 Mar 12. pii: 2762581. doi: 10.1001/jamaoncol.2020.0059.
    PubMed    


  16. OKAMOTO I, Nokihara H, Nomura S, Niho S, et al
    Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2020 Mar 12:e196828. doi: 10.1001/jamaoncol.2019.6828.
    PubMed     Abstract available


  17. FEHLMANN T, Kahraman M, Ludwig N, Backes C, et al
    Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients.
    JAMA Oncol. 2020 Mar 5. pii: 2761984. doi: 10.1001/jamaoncol.2020.0001.
    PubMed     Abstract available


    February 2020
  18. JABBOUR SK, Berman AT, Decker RH, Lin Y, et al
    Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
    JAMA Oncol. 2020 Feb 20. pii: 2761665. doi: 10.1001/jamaoncol.2019.6731.
    PubMed     Abstract available


    January 2020
  19. SKELIN M, Javor E, Lucijanic M
    Association of Early Palliative Care With Survival in Patients With Advanced Lung Cancer.
    JAMA Oncol. 2020 Jan 16. pii: 2758573. doi: 10.1001/jamaoncol.2019.6295.
    PubMed    


  20. SULLIVAN DR, Slatore CG
    Association of Early Palliative Care With Survival in Patients With Advanced Lung Cancer-Reply.
    JAMA Oncol. 2020 Jan 16. pii: 2758574. doi: 10.1001/jamaoncol.2019.6301.
    PubMed    


    December 2019
  21. KICHENADASSE G, Miners JO, Mangoni AA, Rowland A, et al
    Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 Dec 26. pii: 2757521. doi: 10.1001/jamaoncol.2019.5241.
    PubMed     Abstract available


    October 2019
  22. YANG JJ, Yu D, Xiang YB, Blot W, et al
    Association of Dietary Fiber and Yogurt Consumption With Lung Cancer Risk: A Pooled Analysis.
    JAMA Oncol. 2019 Oct 24. pii: 2753175. doi: 10.1001/jamaoncol.2019.4107.
    PubMed     Abstract available


    September 2019
  23. SULLIVAN DR, Chan B, Lapidus JA, Ganzini L, et al
    Association of Early Palliative Care Use With Survival and Place of Death Among Patients With Advanced Lung Cancer Receiving Care in the Veterans Health Administration.
    JAMA Oncol. 2019 Sep 19. pii: 2751526. doi: 10.1001/jamaoncol.2019.3105.
    PubMed     Abstract available


  24. SYKES DB
    Insights From a Patient With Lung Cancer-Party Therapy Is Way Better Than Chemotherapy.
    JAMA Oncol. 2019 Sep 12. pii: 2749689. doi: 10.1001/jamaoncol.2019.2591.
    PubMed    


  25. YIN G, Zhang C
    Reanalysis of Data Comparing Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 Sep 5. pii: 2749254. doi: 10.1001/jamaoncol.2019.3593.
    PubMed    


  26. SUN A, Hu C
    Reanalysis of Data Comparing Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer-In Reply.
    JAMA Oncol. 2019 Sep 5. pii: 2749255. doi: 10.1001/jamaoncol.2019.3602.
    PubMed    


    August 2019
  27. RENGAN R, Mick R, Pryma DA, Lin LL, et al
    Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial.
    JAMA Oncol. 2019 Aug 22. pii: 2748893. doi: 10.1001/jamaoncol.2019.2095.
    PubMed     Abstract available


  28. CATANIA C, Del Signore E, Spitaleri G
    The Desire for Life and Motherhood Despite Metastatic Lung Cancer.
    JAMA Oncol. 2019 Aug 15. pii: 2748397. doi: 10.1001/jamaoncol.2019.2588.
    PubMed    


  29. STINCHCOMBE TE, Janne PA, Wang X, Bertino EM, et al
    Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2019 Aug 8. pii: 2747878. doi: 10.1001/jamaoncol.2019.1847.
    PubMed     Abstract available


    July 2019
  30. TOPALIAN SL, Hodi FS, Brahmer JR, Gettinger SN, et al
    Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.
    JAMA Oncol. 2019 Jul 25. pii: 2738775. doi: 10.1001/jamaoncol.2019.2187.
    PubMed     Abstract available


  31. KAZANDJIAN D, Gong Y, Keegan P, Pazdur R, et al
    Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 Jul 25. pii: 2738768. doi: 10.1001/jamaoncol.2019.1747.
    PubMed     Abstract available


  32. BAUML JM, Mick R, Ciunci C, Aggarwal C, et al
    Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.
    JAMA Oncol. 2019 Jul 11. pii: 2738063. doi: 10.1001/jamaoncol.2019.1449.
    PubMed     Abstract available


  33. THEELEN WSME, Peulen HMU, Lalezari F, van der Noort V, et al
    Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2019 Jul 11. pii: 2738064. doi: 10.1001/jamaoncol.2019.1478.
    PubMed     Abstract available


    June 2019
  34. ALDRICH MC, Mercaldo SF, Sandler KL, Blot WJ, et al
    Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers.
    JAMA Oncol. 2019 Jun 27. pii: 2737091. doi: 10.1001/jamaoncol.2019.1402.
    PubMed     Abstract available


  35. SALEM A, Faivre-Finn C
    Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?-In Reply.
    JAMA Oncol. 2019 Jun 20. pii: 2736365. doi: 10.1001/jamaoncol.2019.1332.
    PubMed    


  36. CHUN SG, Schild SE, Bogart JA
    Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?
    JAMA Oncol. 2019 Jun 20. pii: 2736364. doi: 10.1001/jamaoncol.2019.1326.
    PubMed    


    May 2019
  37. GIRI S, Huntington SF
    Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 May 16. pii: 2733792. doi: 10.1001/jamaoncol.2019.1088.
    PubMed    


  38. CRISS SD, Mooradian MJ, Kong CY
    Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer-In Reply.
    JAMA Oncol. 2019 May 16. pii: 2733793. doi: 10.1001/jamaoncol.2019.1100.
    PubMed    


    April 2019
  39. BERNER F, Bomze D, Diem S, Ali OH, et al
    Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer.
    JAMA Oncol. 2019 Apr 25. pii: 2731134. doi: 10.1001/jamaoncol.2019.0402.
    PubMed     Abstract available


    March 2019
  40. MOR V, Wagner TH, Levy C, Ersek M, et al
    Association of Expanded VA Hospice Care With Aggressive Care and Cost for Veterans With Advanced Lung Cancer.
    JAMA Oncol. 2019 Mar 28. pii: 2729064. doi: 10.1001/jamaoncol.2019.0081.
    PubMed     Abstract available


  41. SUN A, Hu C, Wong SJ, Gore E, et al
    Prophylactic Cranial Irradiation vs Observation in Patients With Locally Advanced Non-Small Cell Lung Cancer: A Long-term Update of the NRG Oncology/RTOG 0214 Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2019 Mar 14. pii: 2728245. doi: 10.1001/jamaoncol.2018.7220.
    PubMed     Abstract available


    February 2019
  42. WANG Z, Duan J, Cai S, Han M, et al
    Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    JAMA Oncol. 2019 Feb 28. pii: 2726029. doi: 10.1001/jamaoncol.2018.7098.
    PubMed     Abstract available


  43. PALMA DA, Nguyen TK, Louie AV, Malthaner R, et al
    Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial.
    JAMA Oncol. 2019 Feb 21. pii: 2725402. doi: 10.1001/jamaoncol.2018.6993.
    PubMed     Abstract available


    December 2018
  44. TOI Y, Sugawara S, Sugisaka J, Ono H, et al
    Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Dec 27. pii: 2718925. doi: 10.1001/jamaoncol.2018.5860.
    PubMed     Abstract available


  45. CRISS SD, Mooradian MJ, Sheehan DF, Zubiri L, et al
    Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
    JAMA Oncol. 2018 Dec 13. pii: 2718006. doi: 10.1001/jamaoncol.2018.5449.
    PubMed     Abstract available


  46. SALEM A, Mistry H, Hatton M, Locke I, et al
    Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
    JAMA Oncol. 2018 Dec 6:e185335. doi: 10.1001/jamaoncol.2018.5335.
    PubMed     Abstract available


  47. WEST HJ
    Moving Beyond Limited and Extensive Staging of Small Cell Lung Cancer.
    JAMA Oncol. 2018 Dec 6. pii: 2717231. doi: 10.1001/jamaoncol.2018.5187.
    PubMed    


    November 2018
  48. CHEN XZ
    Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China.
    JAMA Oncol. 2018 Nov 29. pii: 2716809. doi: 10.1001/jamaoncol.2018.5526.
    PubMed    


  49. SLOAN L, Romo CG, Hales RK
    Hemifacial Hyperhidrosis in a Patient With an Apical Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Nov 15. pii: 2713851. doi: 10.1001/jamaoncol.2018.4597.
    PubMed    


    October 2018
  50. EZE C, Kasmann L, Manapov F
    Redefining the Role of Prophylactic Cranial Irradiation in the Modern Era of Active Surveillance in Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 25. pii: 2707226. doi: 10.1001/jamaoncol.2018.4833.
    PubMed    


  51. GYAWALI B, West HJ
    Plasma vs Tissue Next-Generation Sequencing in Non-Small Cell Lung Cancer-Either, Both, or Neither?
    JAMA Oncol. 2018 Oct 11. pii: 2705603. doi: 10.1001/jamaoncol.2018.4304.
    PubMed    


  52. AGGARWAL C, Thompson JC, Black TA, Katz SI, et al
    Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 11. pii: 2705609. doi: 10.1001/jamaoncol.2018.4305.
    PubMed     Abstract available


  53. BOOZALIS E, Kwatra SG, Marrone KA
    Bilateral Lower Extremity Skin Eruptions in an HIV-Positive Man Receiving Pembrolizumab Monotherapy for Non-Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 4. pii: 2704206. doi: 10.1001/jamaoncol.2018.4485.
    PubMed    


    September 2018
  54. TUMINELLO S, Schwartz RM, Liu B, Mhango G, et al
    Opioid Use After Open Resection or Video-Assisted Thoracoscopic Surgery for Early-Stage Lung Cancer.
    JAMA Oncol. 2018 Sep 24. pii: 2703444. doi: 10.1001/jamaoncol.2018.4387.
    PubMed    


  55. FERRARA R, Mezquita L, Texier M, Lahmar J, et al
    Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    JAMA Oncol. 2018 Sep 6. pii: 2698845. doi: 10.1001/jamaoncol.2018.3676.
    PubMed     Abstract available


    August 2018
  56. GRIDELLI C, de Castro Carpeno J, Dingemans AC, Griesinger F, et al
    Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
    JAMA Oncol. 2018 Aug 30:e183486. doi: 10.1001/jamaoncol.2018.3486.
    PubMed     Abstract available


  57. HAN B, Li K, Wang Q, Zhang L, et al
    Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial.
    JAMA Oncol. 2018 Aug 9. pii: 2696341. doi: 10.1001/jamaoncol.2018.3039.
    PubMed     Abstract available


  58. ALCORN SR, Miller DB, Hales RK
    Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer.
    JAMA Oncol. 2018 Aug 2. pii: 2694876. doi: 10.1001/jamaoncol.2018.3261.
    PubMed    


  59. PASQUINELLI MM, Kovitz KL, Koshy M, Menchaca MG, et al
    Outcomes From a Minority-Based Lung Cancer Screening Program vs the National Lung Screening Trial.
    JAMA Oncol. 2018 Aug 2. pii: 2694875. doi: 10.1001/jamaoncol.2018.2823.
    PubMed    


  60. CHUN SG, Pezzi TA, Schwartz DL
    Underutilization of Combined-Modality Therapy in Limited-Stage Small Cell Lung Cancer-Reply.
    JAMA Oncol. 2018 Aug 2. pii: 2694877. doi: 10.1001/jamaoncol.2018.3292.
    PubMed    


  61. OXNARD GR, Hu Y, Mileham KF, Husain H, et al
    Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib.
    JAMA Oncol. 2018 Aug 2. pii: 2694879. doi: 10.1001/jamaoncol.2018.2969.
    PubMed     Abstract available


    July 2018
  62. GUIDA F, Sun N, Bantis LE, Muller DC, et al
    Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
    JAMA Oncol. 2018 Jul 12:e182078. doi: 10.1001/jamaoncol.2018.2078.
    PubMed     Abstract available


    June 2018
  63. GANDARA DR, Riess JW, Lara PN Jr
    In Search of an Oncogene Driver for Squamous Lung Cancer.
    JAMA Oncol. 2018 Jun 14. pii: 2684629. doi: 10.1001/jamaoncol.2018.0774.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: